TY - JOUR
T1 - The Thompson Encephalopathy Score and Short-Term Outcomes in Asphyxiated Newborns Treated With Therapeutic Hypothermia
AU - Thorsen, Patricia
AU - Jansen-van der Weide, Martine C.
AU - Groenendaal, Floris
AU - Onland, Wes
AU - van Straaten, Henrika L. M.
AU - Zonnenberg, Inge
AU - Vermeulen, Jeroen R.
AU - Dijk, Peter H.
AU - Dudink, Jeroen
AU - Rijken, Monique
AU - van Heijst, Arno
AU - Dijkman, Koen P.
AU - Cools, Filip
AU - Zecic, Alexandra
AU - van Kaam, Anton H.
AU - de Haan, Timo R.
AU - Jansen-van der Weide, Marijke C.
N1 - ISI Document Delivery No.: DR4RM Times Cited: 0 Cited Reference Count: 14 Thorsen, Patricia Jansen-van der Weide, Martine C. Groenendaal, Floris Onland, Wes van Straaten, Henrika L. M. Zonnenberg, Inge Vermeulen, Jeroen R. Dijk, Peter H. Dudink, Jeroen Rijken, Monique van Heijst, Arno Dijkman, Koen P. Cools, Filip Zecic, Alexandra van Kaam, Anton H. de Haan, Timo R. Onland, Wes/0000-0002-9623-0606; Groenendaal, Floris/0000-0002-9284-1637 Dutch Government (ZonMw) [40-41 500-98-9002] Funding for the original "PharmaCool" study has been received by the Dutch Government (ZonMw grant number: 40-41 500-98-9002). 0 1 ELSEVIER SCIENCE INC NEW YORK PEDIATR NEUROL
PY - 2016
Y1 - 2016
N2 - The Thompson encephalopathy score is a clinical score to assess newborns suffering from perinatal asphyxia. Previous studies revealed a high sensitivity and specificity of the Thompson encephalopathy score for adverse outcomes (death or severe disability). Because the Thompson encephalopathy score was developed before the use of therapeutic hypothermia, its value was reassessed. The purpose of this study was to assess the association of the Thompson encephalopathy score with adverse short-term outcomes, defined as death before discharge, development of severe epilepsy, or the presence of multiple organ failure in asphyxiated newborns undergoing therapeutic hypothermia. The study period ranged from November 2010 to October 2014. A total of 12 tertiary neonatal intensive care units participated. Demographic and clinical data were collected from the "PharmaCool" multicenter study, an observational cohort study analyzing pharmacokinetics of medication during therapeutic hypothermia. With multiple logistic regression analyses the association of the Thompson encephalopathy scores with outcomes was studied. Data of 142 newborns were analyzed (male: 86; female: 56). Median Thompson score was 9 (interquartile range: 8 to 12). Median gestational age was 40 weeks (interquartile range 38 to 41), mean birth weight was 3362 grams (standard deviation: 605). All newborns manifested perinatal asphyxia and underwent therapeutic hypothermia. Death before discharge occurred in 23.9% and severe epilepsy in 21.1% of the cases. In total, 59.2% of the patients had multiple organ failure. The Thompson encephalopathy score was not associated with multiple organ failure, but a Thompson encephalopathy score ≥12 was associated with death before discharge (odds ratio: 3.9; confidence interval: 1.3 to 11.2) and with development of severe epilepsy (odds ratio: 8.4; confidence interval: 2.5 to 27.8). The Thompson encephalopathy score is a useful clinical tool, even in cooled asphyxiated newborns. A score ≥12 is associated with adverse outcomes (death before discharge and development of severe epilepsy). The Thompson encephalopathy score is not associated with the development of multiple organ failure
AB - The Thompson encephalopathy score is a clinical score to assess newborns suffering from perinatal asphyxia. Previous studies revealed a high sensitivity and specificity of the Thompson encephalopathy score for adverse outcomes (death or severe disability). Because the Thompson encephalopathy score was developed before the use of therapeutic hypothermia, its value was reassessed. The purpose of this study was to assess the association of the Thompson encephalopathy score with adverse short-term outcomes, defined as death before discharge, development of severe epilepsy, or the presence of multiple organ failure in asphyxiated newborns undergoing therapeutic hypothermia. The study period ranged from November 2010 to October 2014. A total of 12 tertiary neonatal intensive care units participated. Demographic and clinical data were collected from the "PharmaCool" multicenter study, an observational cohort study analyzing pharmacokinetics of medication during therapeutic hypothermia. With multiple logistic regression analyses the association of the Thompson encephalopathy scores with outcomes was studied. Data of 142 newborns were analyzed (male: 86; female: 56). Median Thompson score was 9 (interquartile range: 8 to 12). Median gestational age was 40 weeks (interquartile range 38 to 41), mean birth weight was 3362 grams (standard deviation: 605). All newborns manifested perinatal asphyxia and underwent therapeutic hypothermia. Death before discharge occurred in 23.9% and severe epilepsy in 21.1% of the cases. In total, 59.2% of the patients had multiple organ failure. The Thompson encephalopathy score was not associated with multiple organ failure, but a Thompson encephalopathy score ≥12 was associated with death before discharge (odds ratio: 3.9; confidence interval: 1.3 to 11.2) and with development of severe epilepsy (odds ratio: 8.4; confidence interval: 2.5 to 27.8). The Thompson encephalopathy score is a useful clinical tool, even in cooled asphyxiated newborns. A score ≥12 is associated with adverse outcomes (death before discharge and development of severe epilepsy). The Thompson encephalopathy score is not associated with the development of multiple organ failure
U2 - https://doi.org/10.1016/j.pediatrneurol.2016.03.014
DO - https://doi.org/10.1016/j.pediatrneurol.2016.03.014
M3 - Article
C2 - 27343024
SN - 0887-8994
VL - 60
SP - 49
EP - 53
JO - Pediatric neurology
JF - Pediatric neurology
ER -